Clinical trials: Hepatic Chemotherapy
Colorectal Adenocarcinoma Metastatic in the Liver, Colorectal Cancer
Liver-directed Chemotherapy After Surgery of Liver Metastases of Colorectal Cancer in Patients With High Risk of Recurrence of Their Disease
At the time of diagnosis, 25% of patients with colorectal cancer present with liver metastasis (CRLM). Among patients with localized colorectal cancer (Stages I-III), 50% to 70% will develop liver metastases during the course of…
- Trial name
- PACHA-02 (NCT07284394)
- Testing
- Arterial catheter infusion chemotherapy, IV Chemotherapy (Regimen 1)
- Volunteers
- 272 people
- Sponsor
- UNICANCER
Hepatocellular Carcinoma (HCC)
HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion
The combination of HAIC with systemic therapy can provide superior efficacy compared to systemic therapy alone or local therapy alone for patients with advanced HCC complicated by vascular invasion, regardless of whether they…
- Trial name
- NCT07466225
- Testing
- HAIC, Lenvatinib, PD-1 Inhibitors
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Peking University
Colorectal Cancer
Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases
The main objective is to compare resection rates (R0 or R1) for hepatic metastases in the experimental arm (tri chemotherapy plus targeted therapy) versus the control arm (bi chemotherapy plus targeted therapy); in both arms the…
- Trial name
- NCT01442935
- Testing
- Oxaliplatin, Folinic Acid, 5-FU
- Where
- France
- Volunteers
- 256 people
- Sponsor
- UNICANCER
Hepatocellular Carcinoma
HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven)
The purpose of this prospective, randomized, multicenter, controlled clinical study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) compared to transarterial chemoembolization (TACE) when…
- Trial name
- NCT07594340
- Testing
- Procedure (FOLFOX-HAIC): Max 4 cycles within first 16 weeks., TACE (transarterial chemoembolization) combined with targeted/immunotherapy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Binkui Li
Carcinoma, Carcinoma, Hepatocellular
Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery
This is an open-label，multi-center ，non-randomized ，single arm exploratory study . This clinical study is an investigator-initiated clinical trial（IIT ）.
- Conditions
- Carcinoma, Carcinoma, Hepatocellular, Liver Neoplasms, Digestive System Neoplasms
- Trial name
- NCT04962958
- Testing
- Hepatic arterial infusion chemotherapy, Folfox Protocol, Donafenib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Colorectal Cancer, Metastatic Cancer
Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as melphalan, leucovorin, oxaliplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00103298
- Testing
- FOLFOX regimen, fluorouracil, isolated perfusion
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma
This is a single-arm, exploratory study to evaluate the efficacy and safety of HAIC in combination with sintilimab and bevacizumab in the first line treatment of patients with BCLC-C hepatocellular carcinoma.
- Trial name
- NCT05617430
- Testing
- HAIC, Sintilimab, Bevacizumab Biosimilar IBI305
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Cholangiocarcinoma
Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma
A phase II trial evaluating intra-hepatic chemotherapy with oxaliplatin every second week in combination with systemic gemcitabine and capecitabine in combination with cetuximab in patient with non-resectable liver metastases…
- Trial name
- NCT01247337
- Testing
- Oxaliplatin, capecitabine, gemcitabine, cetuximab, Oxaliplatin, capecitabine, gemcitabine cetuximab
- Where
- Denmark
- Volunteers
- 56 people
- Sponsor
- Dorte Nielsen
Cholangiocarcinoma
Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Tislelizumab and Regorafenib as First-Line Therapy for Advanced Cholangiocarcinoma
The goal of this clinical trial is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with tislelizumab and regorafenib as first-line therapy in patients with locally advanced or…
- Trial name
- NCT07619937
- Testing
- HAIC Combined with Tislelizumab and Regorafenib
- Where
- China
- Volunteers
- 31 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Unrescetable Hepatocellular Carcinoma
HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma
To evaluate the efficacy and safety of HAIC combined with Durvalumab, Tremelimumab and Bevacizumab as first-line therapy in Unresectable hepatocellular carcinoma
- Trial name
- NCT05864755
- Testing
- HAIC+Durvalumab+Tremelimumab+Bevacizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma
P2 Study of Postoperative Interferon/Fluorouracil vs Cisplatin/Fluorouracil for Hepatocellular Carcinoma.
To evaluate the efficacy and safety of postoperative hepatic arterial infusion chemotherapy, interferon/fluorouracil versus low-dose cisplatin/fluorouracil, in patients with hepatocellular carcinoma with portal vein tumor…
- Trial name
- NCT01834963
- Testing
- Interferon Alfa、Fluorouracil, Cisplatin、Fluorouracil
- Where
- Japan
- Volunteers
- 66 people
- Sponsor
- Kansai Hepatobiliary Oncology Group
Resected Liver Metastases From Colorectal Cancer
Alternating Systemic and Hepatic Artery Infusion Therapy As Adjuvant Treatment After Resection of Liver Metastases From Colorectal Cancer
This adaptive seamless Phase II/III trial is to compare the efficacy and safety of adjuvant systemic chemotherapy (SCT) with or without hepatic arterial infusion (HAI) after complete hepatic resection for Chinese patients with…
- Trial name
- NCT02529774
- Testing
- Floxuridine (FUDR),Dexamethasone (DXM), Heparin in combination with Oxaliplatin and Capecitabine (CapeOX) or in combination with Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6), Oxaliplatin and Capecitabine (CapeOX) or Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)
- Where
- China
- Volunteers
- 432 people
- Sponsor
- Ye Xu
Hepatocellular Carcinoma
The Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL) in Advanced Hepatocellular Carcinoma (HCC)
To evaluate the efficacy of HAIC combine Lenvatinib and Durvalumab (HILL) in advanced HCC.
- Trial name
- NCT04961918
- Testing
- Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL)
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial
Our previous study showed that hepatic arterial infusion chemotherapy plus lenvatinib and toripalimab improved the survival of advanced hepatocellular carcinoma.
- Trial name
- NCT06201065
- Testing
- Hepatic arterial infusion chemotherapy, Lenvatinib, Toripalimab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Intrahepatic Cholangiocarcinoma
HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma
Primary liver cancer is the sixth most common cancer worldwide, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, of which intrahepatic cholangiocarcinoma accounts for 10%-15%.
- Trial name
- NCT05290116
- Testing
- HAIC Combined with Tislelizumab and Apatinib
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Yunfei Yuan
Cholangiocarcinoma
HAIC Combined With Donafenib and Sintilimab for Unresectable ICC
To evaluate the safety and tolerability of HAIC combined with donafenib and sintilimab in first-line treatment of unresectable ICC.
- Trial name
- NCT05348811
- Testing
- HAIC combined with donafenib and sintilimab
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Zhongda Hospital
Cancer of the Bile Duct, Gallbladder Cancer
Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer
The purpose of this clinical trial is to determine whether the combination of the established chemotherapeutic agent 5-fluorouracil(5-FU) and the large carbohydrate molecule GM-CT-01 is beneficial in treating advanced gall…
- Trial name
- NCT00386516
- Testing
- GM-CT-01, 5-Fluorouracil
- Where
- 3 sites in United States
- Sponsor
- Galectin Therapeutics Inc.
Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitor
HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC
The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with different tumor burden advanced-stage…
- Conditions
- Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitor, Immune Checkpoint Inhibitors, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT06632106
- Testing
- hepatic artery infusion chemotherapy, Tyrosine kinase inhibitor (TKIs), Immune Checkpoint Inhibitors
- Where
- China
- Volunteers
- 97 people
- Sponsor
- First Hospital of China Medical University
Colorectal Cancer, Metastatic Cancer
Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy work in different ways to kill tumor cells or stop them from growing. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that…
- Trial name
- NCT01189227
- Testing
- Postoperative chemotherapy, Perioperative chemotherapy
- Where
- 283 sites in United States
- Volunteers
- 9 people
- Sponsor
- NSABP Foundation Inc
Colorectal Cancer, Metastatic Cancer
Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver (6655)
RATIONALE: Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping the cells from dividing.
- Trial name
- NCT00023868
- Testing
- FOLFIRI regimen, cisplatin, doxorubicin hydrochloride
- Where
- 9 sites in United States
- Sponsor
- American College of Radiology Imaging Network